New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to...
“We identified a subset of brain tumor cells that are slower growing or remain at rest, and appear to be the source of cancer recurrence after standard therapy in which the drug temozolomide is given to stop the tumor’s growth,” said Dr. Luis Parada. “Current therapy targets fast-growing tumor cells but not those responsible for new tumors. To the best of our knowledge, this is the first identification of a cancer stem-like cell in a spontaneously forming tumor inside a mammal.”
A new drug could help increase the effectiveness of radiation therapy for patients with glioblastoma multiforme, the most deadly form of brain cancer. The ATM kinase inhibitor, in combination with radiation therapy, helped significantly extend survival rates in mouse models of GBM.
Researchers demonstrate melanoma differentiation associated gene, mda-9/syntenin is a driving force behind the aggressive and invasive nature of glioblastoma brain cancer.
Researchers have developed a promising new combination therapy for the treatment of glioblastoma brain cancer.
Researchers report they have discovered an innovative method that may stop the spread of glioblastoma multiforme.
A new nanocarrier meets the size and stability to effectively pass the BBB and deliver drugs to glioblastoma multiforme brain cancer.
Researchers have discovered a key to glioblastoma tumor cells proliferation, and ways to turn this engine of tumor growth into a target for cancer treatment.